Editors' Note: Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial

被引：0
|
作者：
Galetta, Steven
Ganesh, Aravind
Lewis, Ariane
Siegler, James E., III
机构：
来源：
NEUROLOGY | 2022年 / 99卷 / 06期
关键词：
D O I：
10.1212/WNL.0000000000201001
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：258 / 258
页数：1
相关论文
共 33 条
  • [1] Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease Three-Year Outcomes From the PD-1101 Trial
    Christine, Chadwick W.
    Richardson, R. Mark
    Van Laar, Amber D.
    Thompson, Marin E.
    Fine, Elisabeth M.
    Khwaja, Omar S.
    Li, Chunming
    Liang, Grace S.
    Meier, Andreas
    Roberts, Eiry W.
    Pfau, Madeline L.
    Rodman, Josh R.
    Bankiewicz, Krystof S.
    Larson, Paul S.
    NEUROLOGY, 2022, 98 (01) : E40 - E50
  • [2] Author Response: Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial
    Christine, Chadwick W.
    Richardson, R. Mark
    Van Laar, Amber
    Fine, Elisabeth M.
    Khwaja, Omar S.
    Liang, Grace S.
    Bankiewicz, Krystof
    Larson, Paul S.
    NEUROLOGY, 2022, 99 (06) : 260 - 261
  • [3] Three-year safety and clinical outcomes from the PD-1101 trial of AADC gene therapy for advanced Parkinson's disease
    Christine, C.
    Richardson, R.
    Van Laar, A.
    Thompson, M.
    Herbert, K.
    Li, C.
    Liang, G.
    Fine, E.
    Larson, P.
    MOVEMENT DISORDERS, 2020, 35 : S391 - S392
  • [4] VY-AADC01 gene therapy in Parkinson's disease: Interim results of the on-going Phase 1b PD-1101 trial
    Larson, P.
    Bankiewicz, K.
    Van Laar, A.
    Richardson, R.
    Ravina, B.
    Kells, A.
    Boot, B.
    Martin, A.
    Thompson, M.
    Christine, C.
    MOVEMENT DISORDERS, 2018, 33 : S137 - S138
  • [5] The PD-1102 trial in advanced Parkinson's disease: safety and clinical outcomes from a 3-year phase 1b study of AADC gene therapy administered via a posterior approach
    Factor, S.
    Gross, R.
    Van Laar, A.
    Christine, C.
    Larson, P.
    Kostyk, S.
    Lonser, R.
    Fine, E.
    Kwhaja, O.
    Li, C.
    Meier, A.
    Liang, G.
    Roberts, E.
    Richardson, R.
    MOVEMENT DISORDERS, 2021, 36 : S208 - S208
  • [6] Early results from a clinical trial of AADC gene therapy for Parkinson's disease
    Eberling, JL
    Bankiewicz, KS
    McGuire, D
    Aminoff, M
    Christine, C
    Starr, P
    Larson, P
    Jagust, WJ
    NEUROLOGY, 2006, 66 (05) : 276 - 277
  • [7] AADC gene therapy administered via a posterior approach: 18-month results from the PD-1102 trial in advanced Parkinson's disease
    Factor, S.
    Van Laar, A.
    Richardson, R.
    Christine, C.
    Larson, P.
    Kostyk, S.
    Lonser, R.
    Li, C.
    Liang, G.
    Meier, A.
    Fine, E.
    Gross, R.
    MOVEMENT DISORDERS, 2020, 35 : S395 - S395
  • [8] AADC Gene Therapy for Advanced Parkinson's Disease: Interim Results of a Phase 1b Trial
    Ravina, Bernard
    Christine, Chadwick W.
    Larson, Paul S.
    Van Laar, Amber
    Richardson, R. Mark
    Kells, Adrian
    Boot, Brendon
    Martin, Alastair
    Thompson, Marin
    Bankiewicz, Krystof S.
    MOLECULAR THERAPY, 2018, 26 (05) : 32 - 32
  • [9] Intraputaminal AADC gene therapy for advanced Parkinson's disease: Interim Results of a Phase 1b Trial
    Christine, Chadwick
    Bankiewicz, Krzysztoffs
    Van Laar, Amber
    Richardson, Mark
    Ravina, Bernard
    Kells, Adreian
    Boot, Brendon
    Martin, Alastair
    Thompson, Marin
    Larson, Paul
    NEUROLOGY, 2017, 89 (08) : E99 - E99
  • [10] Intraputaminal AADC gene therapy for advanced Parkinson's disease: interim results of a phase 1b Trial
    Ravina, B.
    Christine, C.
    Bankiewicz, K.
    Van Laar, A.
    Richardson, M.
    Kells, A.
    Boot, B.
    Martin, A.
    Thompson, M.
    Larson, P.
    HUMAN GENE THERAPY, 2017, 28 (12) : A6 - A6
1234